Company
Keros Therapeutics, Inc. (KROS)
Standardized SEC financial data for Keros Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001664710 · NASDAQ · Pharmaceutical Preparations.
Operating margin
27.7%
Net margin
35.6%
Return on equity
28.7%
Free cash flow
$106.0M
Current ratio
15.45×
EPS (diluted)
$2.30
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $20.1M | $0 | $151K | $3.5M | $244.1M |
| R&D expense |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $266.0M | $231.4M | $280.4M | $332.4M | $561.4M | $288.9M |
| Total current assets |
Cash flow
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2025 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$70.1M | -$124.5M | -$160.9M | — | — | $107.5M |
| Capital expenditures |
Get KROS data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/KROS/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/KROS/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"